DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females

Information source: Dr Cipto Mangunkusumo General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Urinary Tract Infection

Intervention: Levofloxacin (Drug); Solifenacin succinate (Drug); Placebo (for Solifenacin succinate) (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Dr Cipto Mangunkusumo General Hospital

Summary

The efficacy of Solifenacin Succinate 5 mg as adjuvant therapy and levofloxacin (500 mg) for short-term treatment to reduce symptoms in patients with symptomatic non complicated urinary tract infection in females.

Clinical Details

Official title: The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Symptomatic Non-complicated Urinary Tract Infection in Females

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Number of participants with storage symptoms

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- females (18-65 years old)

- dysuria in symptomatic non complicated urinary tract infection

Exclusion Criteria:

- Pediatric Patients (< 18 years old)

- geriatric Patients (> 65 years old)

- pregnant Patients

- Patients with complicated urinary tract infection

- sexually transmitted infections

- Patients with pathological abnormalities in the urinary bladder, including stone/mass

- Catheter-mounted

- Neurological diseases/disorders

- patients with allergy/hypersensitivity with Levofloxacin/Solifenacin

Locations and Contacts

Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia; Recruiting
Harrina Erlianti Rahardjo, Phone: +62 816-825-226, Email: harrinaerlianti@yahoo.com
Additional Information

Starting date: April 2013
Last updated: March 19, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017